Compile Data Set for Download or QSAR
maximum 50k data
Found 3398 with Last Name = 'simov' and Initial = 'v'
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50584324(CHEMBL5088471)
Affinity DataIC50: <0.0800nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins follo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50152595(CHEMBL3780091)
Affinity DataIC50:  0.100nMAssay Description:Inhibition of JAK1 (unknown origin)More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50355501(INCB-018424 | RUXOLITINIB | RUXOLITINIB PHOSPHATE ...)
Affinity DataIC50:  0.120nMAssay Description:Inhibition of JAK2 (unknown origin)More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50152667(CHEMBL3780636)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of JAK1 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50590228(CHEMBL5172416)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser9...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50193995(3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyr...)
Affinity DataIC50:  0.350nMAssay Description:Inhibition of JAK3 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50590227(CHEMBL5181104)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser9...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50152602(CHEMBL3781442)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of JAK1 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50355501(INCB-018424 | RUXOLITINIB | RUXOLITINIB PHOSPHATE ...)
Affinity DataIC50:  0.430nMAssay Description:Inhibition of JAK1 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMedDrugBank

TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50152666(CHEMBL3781359)
Affinity DataIC50:  0.5nMAssay Description:Inhibition of JAK1 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359566((R or S)-4-(1-(2- chloro-6-(1- (trifluoromethyl)cy...)
Affinity DataIC50:  0.5nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359544(4-{(6R or S)-1-({2- chloro-6-[1- (difluoromethyl)c...)
Affinity DataIC50:  0.5nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359568((R or S)-4-(1-(2- chloro-6-(1- (trifluoromethyl)cy...)
Affinity DataIC50:  0.5nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359569((R or S)-4-(1-(2- chloro-6-(1- (trifluoromethyl)cy...)
Affinity DataIC50:  0.5nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50584331(CHEMBL5079796)
Affinity DataIC50: <0.600nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins follo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50584332(CHEMBL5076397)
Affinity DataIC50: <0.600nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins follo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50152668(CHEMBL3779913)
Affinity DataIC50:  0.600nMAssay Description:Inhibition of JAK1 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359543(4-[(6R or S)-1-({2- chloro-6-[1- (trifluoromethyl)...)
Affinity DataIC50:  0.600nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359545(4-{(6R or S)-1-({2- chloro-6-[1- (trifluoromethyl)...)
Affinity DataIC50:  0.600nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359548(4-{(6R or S)-1-({2- chloro-6-[1- (difluoromethyl)c...)
Affinity DataIC50:  0.600nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50584330(CHEMBL5070497)
Affinity DataIC50: <0.600nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins follo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50584328(CHEMBL5078277 | US20230303540, Example Ex-1.48)
Affinity DataIC50: <0.600nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins follo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50584325(CHEMBL5085777)
Affinity DataIC50: <0.600nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins follo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50584321(CHEMBL5090739)
Affinity DataIC50: <0.600nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins follo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50584318(CHEMBL5082563)
Affinity DataIC50: <0.600nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins follo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50584317(CHEMBL5082260)
Affinity DataIC50: <0.600nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins follo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50584316(CHEMBL5070231)
Affinity DataIC50: <0.600nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins follo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523131(US11161854, Example 11.2)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523096(US11161854, Example 4.20)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523095(US11161854, Example 4.19)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523093(US11161854, Example 4.17)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523092(US11161854, Example 4.16)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523040(US11161854, Example 3.3 | US11161854, Example 4.10)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523087(US11161854, Example 4.12-2)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523088(US11161854, Example 4.13)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523081(US11161854, Example 4.9-1 | US11161854, Example 4....)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523081(US11161854, Example 4.9-1 | US11161854, Example 4....)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359567((R or S)-4-(1-(2- chloro-6-(1- (trifluoromethyl)cy...)
Affinity DataIC50:  0.600nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359570((R or S)-4-(1-(2- chloro-6-(1- (trifluoromethyl)cy...)
Affinity DataIC50:  0.600nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359571((R or S)-4-(1-(2- chloro-6-(1- (trifluoromethyl)c...)
Affinity DataIC50:  0.600nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523028(US11161854, Example 2.4-1 | US11161854, Example 2....)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523034(US11161854, Example 2.7-1 | US11161854, Example 2....)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523038(US11161854, Example 3.1-2)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523042(US11161854, Example 3.5-1 | US11161854, Example 3....)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523051(US11161854, Example 3.6-2 | US11161854, Example 3....)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523061(US11161854, Example 3.8-4)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523069(US11161854, Example 3.11-2 | US11161854, Example 3...)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523072(US11161854, Example 4.1)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523074(US11161854, Example 4.3-1 | US11161854, Example 4....)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523076(US11161854, Example 4.4)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 3398 total ) | Next | Last >>
Jump to: